Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason A Roberts

Showing results (491-500 of 609) with videos related to

Pageof 61
Sort By:
Journal of Clinical Pharmacology|May 12, 2024
Pooled Population Pharmacokinetic Analysis and Dose Recommendations for Ciprofloxacin in Intensive Care Unit Patients with ObesityKoen P van Rhee, Roger J M Brüggemann, Jason A Roberts, et al.
Journal of Paediatrics and Child Health|December 27, 2025
Prolonged Versus Intermittent Beta-Lactam Antibiotic Infusions in Paediatric Critical Care: A Systematic Review and Meta-AnalysisKirsty O'Keefe, Kerina J Denny, Renate Le Marsney, et al.
The Journal of Antimicrobial Chemotherapy|September 10, 2024
Population pharmacokinetics of unbound cefazolin in infected hospitalized patients requiring intermittent high-flux haemodialysis: can a three-times-weekly post-dialysis dosing regimen provide optimal treatment?Carleigh Duke, Suzanne L Parker, Betty B Zam, et al.
Jac-Antimicrobial Resistance|May 28, 2026
Challenges and drivers in the implementation of current practices in outpatient parenteral antimicrobial therapy: an international surveySolomon Ahmed Mohammed, Jason A Roberts, David Nicolás, et al.
Scientific Reports|January 28, 2025
Evaluation of ampicillin plus ceftobiprole combination therapy in treating Enterococcus faecalis infective endocarditis and bloodstream infectionSimone Giuliano, Jacopo Angelini, Floriana Campanile, et al.
The Journal of Antimicrobial Chemotherapy|June 27, 2023
Validating a novel three-times-weekly post-hemodialysis ceftriaxone regimen in infected Indigenous Australian patients-a population pharmacokinetic studyDanny Tsai, Betty B Zam, Carleigh Tongs, et al.
Implementation Science Communications|March 25, 2021
Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods studyErin F Barreto, Andrew D Rule, Mohammad H Alshaer, et al.
Antimicrobial Agents and Chemotherapy|March 8, 2017
Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection ModelPhillip J Bergen, Jürgen B Bulitta, Carl M J Kirkpatrick, et al.
British Journal of Clinical Pharmacology|July 21, 2021
Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: Availability, performance and barriers to implementationIndy Sandaradura, Jan-Willem Alffenaar, Menino O Cotta, et al.
Antimicrobial Agents and Chemotherapy|October 23, 2019
Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill PatientsRajbharan Yadav, Phillip J Bergen, Kate E Rogers, et al.
Pageof 61

Showing results (491-500 of 609) with videos related to

Sort By:
Pageof 61
Journal of Clinical Pharmacology|May 12, 2024
Pooled Population Pharmacokinetic Analysis and Dose Recommendations for Ciprofloxacin in Intensive Care Unit Patients with ObesityKoen P van Rhee, Roger J M Brüggemann, Jason A Roberts, et al.
Journal of Paediatrics and Child Health|December 27, 2025
Prolonged Versus Intermittent Beta-Lactam Antibiotic Infusions in Paediatric Critical Care: A Systematic Review and Meta-AnalysisKirsty O'Keefe, Kerina J Denny, Renate Le Marsney, et al.
The Journal of Antimicrobial Chemotherapy|September 10, 2024
Population pharmacokinetics of unbound cefazolin in infected hospitalized patients requiring intermittent high-flux haemodialysis: can a three-times-weekly post-dialysis dosing regimen provide optimal treatment?Carleigh Duke, Suzanne L Parker, Betty B Zam, et al.
Jac-Antimicrobial Resistance|May 28, 2026
Challenges and drivers in the implementation of current practices in outpatient parenteral antimicrobial therapy: an international surveySolomon Ahmed Mohammed, Jason A Roberts, David Nicolás, et al.
Scientific Reports|January 28, 2025
Evaluation of ampicillin plus ceftobiprole combination therapy in treating Enterococcus faecalis infective endocarditis and bloodstream infectionSimone Giuliano, Jacopo Angelini, Floriana Campanile, et al.
The Journal of Antimicrobial Chemotherapy|June 27, 2023
Validating a novel three-times-weekly post-hemodialysis ceftriaxone regimen in infected Indigenous Australian patients-a population pharmacokinetic studyDanny Tsai, Betty B Zam, Carleigh Tongs, et al.
Implementation Science Communications|March 25, 2021
Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods studyErin F Barreto, Andrew D Rule, Mohammad H Alshaer, et al.
Antimicrobial Agents and Chemotherapy|March 8, 2017
Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection ModelPhillip J Bergen, Jürgen B Bulitta, Carl M J Kirkpatrick, et al.
British Journal of Clinical Pharmacology|July 21, 2021
Emerging therapeutic drug monitoring of anti-infective agents in Australian hospitals: Availability, performance and barriers to implementationIndy Sandaradura, Jan-Willem Alffenaar, Menino O Cotta, et al.
Antimicrobial Agents and Chemotherapy|October 23, 2019
Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill PatientsRajbharan Yadav, Phillip J Bergen, Kate E Rogers, et al.
Pageof 61